Advancing biologic compound design through systematic development from lead discovery to pre-clinical study.
Our systematic approach to candidate development ensures rigorous validation at each stage. Computational approaches accelerate discovery and lead optimization stages of ligand design.
Target ID and Compound Design
1-2 monthsLead Compound Refinement
1-6 monthsIn-vivo Safety and Efficacy
12-24 monthsInvestigational New Drug Application
3-6 monthsHuman Clinical Trials (Phase I-III)
3-7 yearsOur current portfolio of innovative compounds addressing current unmet needs.
Novel peptidomimetic compound targeting Human rhinovirus (HRV) for treatment of common cold and respiratory infections, as well as hepatitis A, polio, and other picornaviruses.
Complete lead optimization studies
Selective peptidomimetic based drugs against CARD-11 (caspase recruiting domain) signaling complex for the treatment of loss-of-function associated diseases such as immune deficiency disorders and atopic dermatitis, as well as gain-of-function mutations associated disease such as BENTA.
Complete target validation
Advanced biosensor technology for monitoring insulin resistance using peptidomimetic recognition elements.
Molecular Recognition Unit Validation
Our diverse portfolio spans multiple therapeutic areas and development stages.